China Cell Biology Industry Conference and Biopharmaceutical Innovation & Cooperation Conference

The China Biotechnology Industry Conference and the Biopharmaceutical Innovation & Cooperation Conference (CBIC) will cover key areas including antibody therapeutics, stem cells and regenerative medicine, immune cell therapy, cell-based drugs, 3D cell culture, cellular multi-omics, organoids, exosomes, target discovery, pharmaceutical innovation, next-generation vaccines, gene therapy, oncolytic viruses, and more. The conferences will focus on hot topics such as the latest advances in biotechnology, clinical applications, industrialization progress, investment and financing opportunities, industry standardization, and emerging regulatory trends.

The biopharmaceutical industry is one of China’s strategic emerging industries prioritized for development. Currently, China ranks second globally in the pharmaceutical market, behind only the United States, and is undergoing a critical strategic transition from “generic drugs” to “innovative medicines.” Precision medicine is driving a revolution in drug discovery, while gene technologies and cell engineering are bringing transformative changes to disease treatment. Medical devices are moving toward intelligence and standardization, offering novel diagnostic and therapeutic approaches. Meanwhile, emerging biopharmaceutical service models—such as contract research organizations (CROs), contract manufacturing organizations (CMOs), third-party testing, and health management—are rapidly expanding, propelling the sector into a phase of rapid growth. (Copyright of this content belongs to Juzhan; unauthorized reproduction is prohibited.)

In recent years, national and local governments have introduced a series of policies to foster the development of the bioeconomy. Among these, three major regional clusters have emerged: the Bohai Rim, led by Beijing, Tianjin, Hebei, and Shandong; the Yangtze River Delta, with Shanghai at its core and Jiangsu and Zhejiang as its wings; and the Pearl River Delta, spearheaded by Guangzhou and Shenzhen. These three regions have become distinct hubs for biopharmaceutical innovation, gaining significant competitive advantages in the industry.

The China Biotechnology Industry Conference and the Biopharmaceutical Innovation & Cooperation Conference (CBIC) bring together academia, innovative pharmaceutical companies, research institutions, hospitals, biotech firms, health‑management providers, medical‑aesthetic enterprises, venture capital and private equity investors, industrial parks, industry associations, and government regulatory bodies. Renowned experts and leading practitioners from across these fields convene to discuss the current state and future prospects of the industry, sharing new opportunities for growth.

Concurrent with the CBIC, related thematic exhibitions will showcase the latest products, technologies, and services in the sector. By consolidating nationwide biopharmaceutical resources, the conference provides participants with a one-stop platform for academic exchange, channel matchmaking, market expansion, and brand promotion, empowering the industry to achieve leapfrog development.

China Cell Biology Industry Conference and Biopharmaceutical Innovation & Cooperation Conference tickets are e-tickets. Mainland China visitors must complete online pre-registration with real-name ID verification; overseas visitors must use passport verification; Hong Kong, Macao, and Taiwan visitors must use their travel permit. On site, verify entry with your ID card or by scanning the e-ticket QR code.

Partial exhibitor directory and exhibitor list for China Cell Biology Industry Conference and Biopharmaceutical Innovation & Cooperation Conference: 杭州普罗亭医学检验实验室有限公司, 厦门特宝生物工程股份有限公司, 天津天诚新药评价有限公司, 劲帆生物医药科技(武汉)有限公司, 艾力特生物科技（上海）有限公司, and others. The 2026 edition is expected to feature 500+ exhibiting companies. To obtain the full exhibitor directory (including booth numbers and contact details), please visit the official exhibition website or contact Jufair.